Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Pharmacokinetics and Pharmacodynamics

• Publication date

  2012-07-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s10928-012-9262-4PMID 22791078
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Prolactin Gene: A Paradigm of Tissue-Specific Gene Regulation with Complex Temporal Transcription Dynamics

  2012cited by this paper
• Systemic and Direct Nose-to-Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration

  2011cited by this paper
• Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin.

  2010cited by this paper
• Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples.

  2010cited by this paper
• A New Minimal-Stress Freely-Moving Rat Model for Preclinical Studies on Intranasal Administration of CNS Drugs

  2009cited by this paper
• Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.

  2009cited by this paper
• Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells.

  2009cited by this paper
• Quantitative Pharmacology or Pharmacokinetic Pharmacodynamic Integration Should Be a Vital Component in Integrative Pharmacology

  2009cited by this paper
• An Agonist–Antagonist Interaction Model for Prolactin Release Following Risperidone and Paliperidone Treatment

  2009influential reference
• What can we learn from rodents about prolactin in humans?

  2008cited by this paper
• Extensions to the Visual Predictive Check to facilitate model performance evaluation

  2008cited by this paper
• Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

  2008cited by this paper
• Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

  2007cited by this paper
• Identification of Amino Acid Determinants of Dopamine 2 Receptor Synthetic Agonist Function

  2007cited by this paper
• Allometric Scaling of Pharmacodynamic Responses: Application to 5-Ht1A Receptor Mediated Responses from Rat to Man

  2007cited by this paper
• Animal-to-Human Extrapolation of the Pharmacokinetic and Pharmacodynamic Properties of Buprenorphine

  2007cited by this paper
• Effect of social isolation on 24-h pattern of stress hormones and leptin in rats.

  2006cited by this paper
• Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist

  2005cited by this paper
• Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling

  2005cited by this paper
• Regional distribution and in vivo binding of the atypical antipsychotic drug remoxipride. A biochemical and autoradiographic analysis in the rat brain

  2005cited by this paper
• Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of 5-HT1A Receptor Agonists: Estimation of in Vivo Affinity and Intrinsic Efficacy on Body Temperature in Rats

  2004cited by this paper
• Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalogram Effects of GABAA Receptor Modulators: In Vitro-in Vivo Correlations

  2003cited by this paper
• Regulation of acetylcholine synthesis and storage.

  2002cited by this paper
• Neuroactive Steroids Differ in Potency but Not in Intrinsic Efficacy at the GABAA Receptor in Vivo

  2002cited by this paper
• Use of Prior Information to Stabilize a Population Data Analysis

  2002cited by this paper
• Prolactin: structure, function, and regulation of secretion.

  2000cited by this paper
• Methodological issues in microdialysis sampling for pharmacokinetic studies.

  2000cited by this paper
• A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog.

  2000cited by this paper
• Prolactin and antipsychotic medications: mechanism of action.

  1999cited by this paper
• Estrogen-Induced Activation of Mitogen-Activated Protein Kinase in Cerebral Cortical Explants: Convergence of Estrogen and Neurotrophin Signaling Pathways

  1999cited by this paper
• Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration.

  1999cited by this paper
• Dopamine receptors: from structure to function.

  1998cited by this paper
• Species‐specificity of growth‐promoting effects of prolactin during rat embryogenesis

  1998cited by this paper
• Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors.

  1997cited by this paper
• Prolactin signal transduction mechanisms in the mammary gland: the role of the Jak/Stat pathway.

  1996cited by this paper
• Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects.

  1995cited by this paper
• Rapid stimulation of mitogen-activated protein kinase of rat liver by prolactin.

  1994cited by this paper
• Prolactin receptor immunoreactivity in rat anterior pituitary.

  1994cited by this paper
• Disposition of remoxipride in different species. Species differences in metabolism.

  1993cited by this paper
• Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.

  1993cited by this paper
• Distribution of remoxipride to the human brain and central D2‐ dopamine receptor binding examined in vivo by PET

  1990cited by this paper
• Immunocytochemical analysis of prolactin cells in the adult rat adenohypophysis: distribution and quantitation relative to sex and strain.

  1986cited by this paper
• Pars distalis cell quantification in normal adult male and female rats.

  1984cited by this paper
• Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics

  1982cited by this paper
• Prolactin cells in the human pituitary. A quantitative immunocytochemical analysis.

  1982cited by this paper
• The effect of exposure to ether on prolactin secretion and the half-life of endogenous prolactin in normal and castrated male rats.

  1978cited by this paper

• Pharmacokinetics of intranasal drugs, still a missed opportunity?

  2024cites this paper
• Exploring New Avenues In Drug Discovery And Development: Insight Into Pharmacokinetics And Pharmacodynamics

  2024cites this paper
• External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients.

  2023cites this paper
• Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia

  2023cites this paper
• Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery.

  2021cites this paper
• Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine

  2020cites this paper
• Dynamical Aspects of Pharmacokinetic/Pharmacodynamic & Quantitative Systems Pharmacology Models

  2020cites this paper
• Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling

  2020cites this paper
• Functional Measurements of Central Nervous System Drug Effects in Early Human Drug Development

  2019cites this paper
• Functional Measurements of Central Nervous System Drug Effects in Early Human Drug Development

  2019cites this paper
• Pharmacokinetic and Pharmacodynamic Properties of Rosmarinic Acid in Rat Cholestatic Liver Injury

  2018cites this paper
• FINGERPRINTS OF CNS DRUG EFFECTS: A PLASMA NEUROENDOCRINE REFLECTION OF D2 RECEPTOR ACTIVATION USING MULTI-BIOMARKER PK/PD MODELING

  2018cites this paper
• DYNAMICAL ANALYSIS OF BLOOD-BASED SYSTEMS BIOMARKERS OF CENTRAL NERVOUS SYSTEM DRUGS

  2018cites this paper
• Modelling the delay between PK and EEG effects of morphine in rats ; binding kinetic versus effect compartment models

  2018cites this paper
• Access to the CNS: Biomarker Strategies for Dopaminergic Treatments

  2018cites this paper
• Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics

  2018influential citation
• Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models

  2018cites this paper
• Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of D 2 receptor activation using multi‐biomarker pharmacokinetic/pharmacodynamic modelling

  2018cites this paper
• Correction to: Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models

  2018cites this paper
• University of Groningen Modeling of prolactin response following dopamine Dreceptor antagonists in rats

  2018cites this paper
• Impact of mathematical pharmacology on practice and theory: four case studies

  2017cites this paper
• Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics

  2017cites this paper
• Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats

  2017cites this paper
• Target-Site Investigation for the Plasma Prolactin Response: Mechanism-Based Pharmacokinetic-Pharmacodynamic Analysis of Risperidone and Paliperidone in the Rat

  2017influential citation
• Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?

  2017influential citation
• Modeling the Effect of the Selective S1P1 Receptor Modulator Ponesimod on Subsets of Blood Lymphocytes

  2016cites this paper
• A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.

  2016cites this paper
• A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations

  2016cites this paper
• Systems pharmacology - Towards the modeling of network interactions.

  2016cites this paper
• Understanding the Behavior of Systems Pharmacology Models Using Mathematical Analysis of Differential Equations: Prolactin Modeling as a Case Study

  2016influential citation
• Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling

  2016influential citation
• Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats

  2016cites this paper
• Intracerebral microdialysis in blood-brain barrier drug research with focus on nanodelivery.

  2016cites this paper
• Blood–brain barrier and drug delivery

  2015cites this paper
• PBPK Modeling Approach for Predictions of Human CNS Drug Brain Distribution

  2015cites this paper
• Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models

  2015cites this paper
• Prediction of brain target site concentrations on the basis of CSF PK: Impact of mechanisms of blood-to-brain transport and within brain distribution

  2015cites this paper
• Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans

  2015cites this paper
• Translational aspects of blood–brain barrier transport and central nervous system effects of drugs: From discovery to patients

  2015cites this paper
• Pharmacometrics in Psychiatric Diseases

  2014cites this paper
• Pharmacokinetic Concepts in Brain Drug Delivery

  2014cites this paper
• Innovative in vitro method and permeability estimation procedure to predict drug transport across the blood-brain barrier

  2014cites this paper
• Prediction of brain target site concentrations on the basis of CSF PK: General discussion and perspectives

  2014cites this paper
• PKPD Aspects of Brain Drug Delivery in a Translational Perspective

  2014cites this paper
• Towards predictive cardiovascular safety : a systems pharmacology approach

  2014cites this paper
• Drug Discovery Methods for Studying Brain Drug Delivery and Distribution

  2014cites this paper
• Use of predictive models in CNS diseases.

  2014cites this paper
• The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives.

  2013cites this paper
• The mastermind approach to CNS drug therapy: translational prediction of human brain distribution, target site kinetics, and therapeutic effects

  2013influential citation
• White Paper: Landscape on Technical and Conceptual Requirements and Competence Framework in Drug/Disease Modeling and Simulation

  2013cites this paper
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowninfluential citation
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowncites this paper
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowncites this paper
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowninfluential citation
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowncites this paper
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowncites this paper
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowncites this paper
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowncites this paper
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowninfluential citation
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowninfluential citation
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowncites this paper
• Multi-biomarker pharmacokinetic-pharmacodynamic relationships of central nervous systems active dopaminergic drugs

  year unknowncites this paper